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R E V I E W
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Abstract: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity 
and mortality. Early detection and appropriate treatment and management of COPD can 
lower morbidity and perhaps mortality. Clinicians in the primary care setting provide the 
majority of COPD care and are pivotal in the diagnosis and management of COPD. In this 
review, we provide an overview of the Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) 2020 report, with a focus on the management of COPD in the primary 
care setting. We discuss the pathophysiology of COPD; describe COPD risk factors, signs, 
and symptoms that may facilitate earlier diagnosis of COPD; and reinforce the importance of 
spirometry use in establishing the diagnosis of COPD. Disease monitoring, as well as 
a review of the 2020 GOLD treatment recommendations, is also discussed. Patients and 
families are important partners in COPD management; therefore, we outline simple steps that 
may assist them in caring for those affected by COPD. Finally, we discuss nonpharmacolo-
gical treatment options for COPD, COPD monitoring tools that may aid in the evaluation of 
disease progression and response to therapy, and the importance of developing a COPD 
action plan on an individualized basis. 
Keywords: COPD, LABA, LAMA, primary care
Introduction
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and 
mortality. COPD is the seventh leading cause of years of life lost globally, and lower 
respiratory disease is the fourth leading cause of death in the United States.1,2 In the 
United States, the age-standardized COPD-related death rate was 39.1 deaths per 
100,000 in 2014 (44.3 in men and 35.6 in women per 100,000).3 COPD symptoms 
can be debilitating and prevent patients and their families from leading normal lives. 
Because of breathlessness, the level of daily physical activity is typically lower in 
patients with COPD than in healthy controls.4 Additionally, patients with COPD often 
have comorbidities such as anxiety, depression, osteoporosis, and cardiovascular 
disease,5 which further impact their overall health, quality of life (QoL), functional 
status, and clinical outcomes. COPD is also associated with substantial socioeconomic 
impact, with high direct and indirect costs—estimated at $36 billion annually—bur-
dening the health care system.6 Direct costs predominantly result from exacerbations 
leading to emergency department (ED) visits, hospital admissions and readmissions, 
and unscheduled office visits.6,7 Clearly, COPD impacts not only patients but also the 
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society as a whole and this impact can be reduced with early 
identification and appropriate treatment and management.8,9
The Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) report includes recommended strategies 
for the diagnosis, treatment, and management of COPD.5 
The COPD Foundation (COPDF) also provides a brief, 
point-of-care pocket consultant guide that serves as 
a short summary to aid clinical decision-making during 
office, ED, or hospital visits.10 In this review, we provide 
an overview of the GOLD 2020 report, with a focus on 
recommendations for the treatment and management of 
COPD in the primary care setting.
Pathophysiology of COPD
COPD results from chronic inflammation of the airways, 
which leads to thickening of airway walls, increased 
mucus production, and eventually permanent changes in 
lung structure11 (Figure 1). Lung changes may include the 
destruction of lung parenchyma including air sac (alveo-
lar) walls, resulting in fibrosis of the small airways 
(emphysema) and loss of elasticity.12 These structural 
changes may cause increased resistance to airflow, signifi-
cant air trapping, and ultimately hyperinflation, all of 
which may manifest as breathlessness, cough, and 
increased phlegm production.11
Chronic lung inflammation in COPD is generally char-
acterized by increased neutrophils, activated macrophages, 
and activated CD8+ T lymphocytes.12 The predominant 
increase in types of inflammatory cells differs between 
COPD and asthma (Table 1).12 Macrophages facilitate 
the recruitment of other inflammatory cells (such as neu-
trophils) and the release of mediators and proteases, which 
may lead to emphysema.13 A subset of COPD patients 
have predominant eosinophilic inflammation even in the 
absence of exacerbations.14
Patients and families require accurate but simple explana-
tions of COPD pathophysiology that can help them understand 
this chronic condition, its symptoms, and recommended phar-
macological and nonpharmacological therapies. For example, 
when discussing dyspnea or shortness of breath, clinicians can 
explain that patients with even mild-to-moderate COPD can 
inhale a high volume of air (approaching total lung capacity). 
However, they may be able to exhale only a portion of the 
inhaled volume, resulting in air trapping and hyperinflation.15 
As patients breathe more rapidly (eg, during exercise), they 
have even shorter time for exhalation and, less and less “room” 
to breathe in (ie progressively increased end-expiratory lung 
volume and decreased inspiratory capacity), both of which 
enhance dyspnea or shortness of breath because of inability 
to “get air in.” This phenomenon can be illustrated by asking 
the patient to take a deep breath in, exhale only a small amount 
of the breath (air trapping), and then attempt to take in three 
quick breaths. The patient will experience acute dyspnea and 
discomfort, as they will have more difficulty with inhalation 
because of residual air in the lungs (ie hyperinflation). This 
maneuver mimics what happens with hyperinflation during 
rest (static hyperinflation) and also during increased activity 
(dynamic hyperinflation) when the respiratory rate is faster.15 
Exertion leaves less time to exhale and, consequently no room 
to let new air in. Common descriptors of air trapping, which 
are important to know to understand patients’ experiences and 
estimating disease severity, include “air hunger,” “unsatisfied” 
or “unrewarded” inhalation, “shallow breathing,” “suffocat-
ing,” and “cannot get a deep breath.”15,16
Patient Presentation
Patients with COPD commonly present with dyspnea, 
chronic cough, and/or sputum production, and occasionally 
Figure 1 Pathophysiology of chronic obstructive pulmonary disease. During the 
time course of COPD, inflammation of the airways can lead to thickening of the 
airway walls, increased mucus production, and damage to alveoli and alveolar ducts 
that leads to enlargement of the air spaces/emphysema, and potentially to air- 
trapping.11
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wheezing (Table 1).5 Unfortunately, delayed diagnosis is 
common and many patients present only after they have 
experienced ≥1 exacerbation, often mistakenly labeled as 
recurrent bronchitis.17 Early diagnosis and treatment are 
essential to improve patients’ lung function, functional sta-
tus, and QoL, and to reduce exacerbations.18 COPD can be 
detected early on if the clinicians consider COPD as part of 
their differential diagnosis. For example, when a patient is 
>40 years old and has recurrent acute bronchitis or bad colds 
that last for weeks, COPD should be suspected even if the 
patient is a nonsmoker. Of note, women are less likely to be 
suspected of having or diagnosed with COPD than men with 
similar symptoms,19 possibly because, COPD traditionally 
was considered a “male” disease. However, various factors, 
including smoking, have contributed to the rising prevalence 
of COPD in women.20 Clinicians can also increase the like-
lihood of detecting COPD by asking targeted questions 
focused on respiratory symptoms (eg, changes in the ability 
to do activities or changes in lifestyle because of shortness of 
breath). Patients often attribute these symptoms to being 
“old, overweight, or out of shape”. Questions such as “Do 
you get or have you ever gotten short of breath when you 
climb a flight of stairs or walk up a hill?” are more specific 
and easier for patients to answer than a vague question such 
as “Do you get short of breath?” Useful tools that are avail-
able to identify and assess baseline symptomatology can be 
used to monitor changes in severity over time. The modified 
Medical Research Council (mMRC) dyspnea scale com-
prises five statements that describe a range of dyspnea effects 
in increasing order of severity. Use of this questionnaire is 
recommended in the GOLD 2020 report5 (Supplementary 
Table 1). Although this questionnaire may be helpful for the 
initial identification of breathlessness and support evaluation 
for COPD,21 it is less useful for monitoring over time 
because moving from one grade to the next requires a very 
large change in functional abilities. Alternatively, the COPD 
Assessment Test (CAT), comprising eight items that are each 
scored using a 6-point scale (0–5), is useful in assessing the 
symptomatic impact of COPD. A higher CAT score indicates 
poorer health. CAT is more sensitive in detecting improve-
ments with treatment or a decline of disease progression or 
exacerbations (Supplementary Figure 1).5,22 Supplementary 
Videos 1 and 2.
COPD Risk Factors
In addition to understanding patients’ symptoms, knowl-
edge of COPD risk factors is important. As major risk 
factors for COPD, current and past smoking history must 
be assessed.5 Nonsmokers exposed to second-hand smoke 
in childhood and adult years are also at an increased risk 
of developing COPD.23 Cigarette smoking was rated as the 
cause of COPD in 50%–70% of patients in developed 
countries.24 Genetics also contributes to the risk of devel-
oping COPD. In a meta-analysis of genome-wide associa-
tion studies, several genetic loci were associated with 
COPD pathophysiology.25 Serine protease α1-antitrypsin 
deficiency, found in 1%–3% of patients with COPD, is the 
most widely reported genetic factor that increases COPD 
risk.26 Other COPD risk factors include occupational 
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very late activation antigen-1.
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exposure (eg, to dust, vapors, organic materials, fumes, 
and chemicals), indoor and outdoor air pollutants (includ-
ing biomass fuels), and aging.5
Diagnosis
Diagnosis begins with clinical suspicion, usually in 
patients who report shortness of breath with activity. 
Overall, symptomatic, at-risk individuals who require 
spirometry and evaluation for COPD include those with 
recurring respiratory events (eg, acute bronchitis, bad 
colds, chronic cough, and excess sputum production), his-
tory of risk factors, decrease in activities because of dys-
pnea, and/or a family history of COPD.5
Spirometry is essential and required to confirm 
a COPD diagnosis.5 It also is useful for tracking treatment 
response, potentially adjusting medications, and monitor-
ing disease progression. When rapid disease progression is 
identified, further evaluation and referral to a lung specia-
list are indicated.5 A postbronchodilator (10–15 minutes 
after 2–4 puffs of a short-acting bronchodilator) forced 
expiratory volume in 1 second (FEV1) to forced vital 
capacity (FVC) ratio of <0.70 confirms the presence of 
persistent or fixed airflow limitation. FVC is the maximal 
volume of air that can be forcibly exhaled after taking in 
the deepest breath possible, and FEV1 is the maximal 
volume of air exhaled in the first second during an FVC 
maneuver (Figure 2).5
Despite recommendations, spirometry is not regularly 
used in clinical practice.27 Underuse of spirometry in pri-
mary care settings is attributed to uncertainty about the 
benefit of COPD diagnosis, lack of time and resources, 
unfamiliarity with the technique, and/or difficulty in inter-
preting results.28,29 However, spirometry is required to con-
firm a COPD diagnosis, can be performed in primary care 
practice using an office-based system,30 and is a billable 
procedure reimbursed by payors. Although patients can be 
referred to specialists and hospitals for spirometry, follow- 
through may be limited; therefore, spirometry can and 
should be done in primary care offices.31
Assessment of Airflow Limitation 
Severity, Symptoms, and Exacerbation 
Frequency
Once a COPD diagnosis is confirmed, spirometry findings can 
also be used to determine the severity of airflow limitations 
(Figure 2), which is based on the patient’s FEV1 relative to 
normal values.5 However, treatment decisions are based on 
symptoms and history of exacerbations treated at home and in 
the hospital. Per the GOLD 2019 report, symptom burden and 
exacerbation frequency in the prior year are used to categorize 
patients into GOLD group A (few symptoms and 0–1 exacer-
bations not leading to hospitalization), group B (more symp-
toms and 0–1 exacerbations not leading to hospitalization), 
group C (few symptoms but ≥2 exacerbations or ≥1 exacerba-
tion leading to hospitalization), or group D (more symptoms 
and ≥2 exacerbations or ≥1 exacerbation leading to hospitaliza-
tion) to guide initial pharmacological therapy (Figure 2).5
Treatment of COPD
After categorizing a patient as belonging to GOLD group 
A, B, C, or D, the GOLD treatment algorithm (Figure 2) 
can be used to determine appropriate initial pharmacolo-
gical treatment, which should be complemented with non-
pharmacological approaches as appropriate.
Pharmacological Interventions
Bronchodilators—the first-choice pharmacotherapy for COPD 
across all patient groups—increase airway diameter and decrease 
air trapping, thereby improving airflow and reducing dyspnea.5 
GOLD group A patients should be offered a bronchodilator (short- 
or long-acting), if symptoms are present. A long-acting muscarinic 
antagonist (LAMA) or a long-acting β2-agonist (LABA) is sug-
gested as initial treatment for GOLD group B patients, and— 
because of their complementary mechanisms of action—dual 
bronchodilator therapy with a LAMA and a LABA can be con-
sidered for highly symptomatic (CAT score ≥20) patients. LAMA 
monotherapy improves lung function and reduces exacerbations 
and is suggested for initial pharmacological treatment in GOLD 
group C (Figure 2). While initial therapy with LAMA is recom-
mended for group GOLD group D patients, starting with a LAMA 
+LABA combination may be more appropriate because many of 
these patients are highly symptomatic (eg, CAT >20). Although 
commonly used as monotherapy for asthma control, inhaled corti-
costeroids (ICS) are not approved worldwide for use as mono-
therapy in COPD patients of any severity. Long-term ICS use is 
associated with safety concerns such as an increased risk of 
pneumonia, active tuberculosis, and osteoporosis.32 However, 
LABA+ICS may be the first-choice treatment in COPD GOLD 
group D patients with a history of asthma or blood eosinophil 
counts ≥300 cells/μL.5 Once recommended initial therapy is 
implemented, patients should be reassessed for treatment response. 
According to recommendations in the GOLD 2020 report, if 
response to initial therapy is not appropriate, follow-up treatment 
based on the patients’ symptoms and exacerbations—and not on 
their initial GOLD group classification—should be provided 
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Figure 2 Diagnosis, assessment, initial, and follow-up treatment of COPD. 
Notes: Reproduced with permission from Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Prevention, Diagnosis, and Management of Chronic 
Obstructive Pulmonary Disease. 2020. https://goldcopd.org.5 
Abbreviations: CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; 
GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroids; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; mMRC, 
modified Medical Research Council dyspnea scale.
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(Figure 2). Separate treatment algorithms are provided based on 
the need to treat dyspnea or prevent exacerbations.
For patients with persistent breathlessness or exercise 
limitation despite long-acting bronchodilator monotherapy,5 
step-up to a LAMA+LABA is recommended. If dual bronch-
odilator therapy does not improve symptoms, step down to 
monotherapy, or switching inhalers or molecules are recom-
mended. When patients experience persistent breathlessness 
or exercise limitation despite LABA+ICS therapy, triple 
therapy with a LAMA+LABA+ICS may be considered. 
However, if ICS was inappropriately indicated to treat 
patients without a history of exacerbations, caused side 
effects, or did not yield any response, switching to 
a LAMA+LABA is recommended.
For patients who continue to experience exacerbations 
despite long-acting bronchodilator monotherapy, step-up to 
a LAMA+LABA or LABA+ICS (in patients with a history 
of hospitalizations for COPD exacerbations, with ≥2 
moderate COPD exacerbations per year, eosinophil counts 
>300 cells/μL, or a history of asthma) is recommended.5 For 
patients who continue to exacerbate despite maximal LAMA 
+LABA, triple therapy is recommended if eosinophil counts 
≥100 cells/μL and roflumilast or azithromycin is recom-
mended if eosinophil counts <100 cells/μL.
While ICS therapy has a role in COPD management, there 
may be a current over-use based on the GOLD 2020 treatment 
algorithms.33 In 2019, some of the recommendations sur-
rounding the use of ICS in GOLD were changed due to 
concerns of over-use of ICS, but these recommendations 
were revised in 2020 to reflect the importance of ICS in certain 
circumstances, such as hospitalization for exacerbation. 
Whether, when, and how non-recommended ICS treatment 
can be withdrawn safely should be considered, particularly in 
patients who had ICS initiated despite no or infrequent exacer-
bations, especially if they also have low eosinophil counts. In 
the INSTEAD trial,34 non-exacerbating patients with moder-
ate COPD were switched from salmeterol+fluticasone (a 
LABA+ICS) to indacaterol (a LABA) without a significant 
change in exacerbation rate. Patients in this trial were at low 
risk of exacerbations and should not have been prescribed ICS 
based on the GOLD 2020 treatment algorithm. Similarly, 
withdrawal of ICS did not increase exacerbation rates in the 
WISDOM35 and SUNSET36 trials, which included patients 
with severe/very severe and moderate-to-severe COPD, 
respectively.
To avoid potentially difficult decisions regarding step-
ping down treatment, ICS should be initiated only when 
recommended, and not in patients with no or infrequent 
exacerbations or in patients whose exacerbations can be 
controlled with dual bronchodilator therapy.
In addition to deciding on appropriate initial and mainte-
nance medications, COPD clinicians should also consider 
which inhaler is optimal for each patient. Prescribing an inha-
ler based on patient characteristics and preferences, and train-
ing patients on correct inhaler use, will lead to better 
adherence.5 During follow-up, inhaler technique and adher-
ence should be assessed. If not optimal, switching to 
a different inhaler device may be considered.5
Nonpharmacological Interventions
Pharmacological therapy for COPD should be complemen-
ted with nonpharmacological approaches, including beha-
vioral therapies and pulmonary rehabilitation, as 
appropriate. Assessment of smoking history and initiation 
of a cessation program, if necessary, must be a part of all 
COPD patients’ treatment plans. Because relapses are com-
mon, smoking status and second-hand smoke exposure 
should be continually monitored over time. Reinforcement 
to remain a sustained quitter or encouragement to stop smok-
ing should be given at each opportunity.
Other nonpharmacological approaches at diagnosis, based 
on GOLD 2020, include referring GOLD group A-D patients 
to pulmonary rehabilitation including exercise training, pro-
moting physical activity, encouraging adherence to the pre-
scribed medication, and prescribing vaccinations.5 
Recommendations for nonpharmacological management of 
COPD at diagnosis and during follow-up are summarized in 
Figure 3. Teaching COPD patients breathing techniques aimed 
at improving respiratory muscle strength and decreasing air 
trapping in the lungs, which can reduce the sense of dyspnea is 
also beneficial.5 Pursed-lip breathing, which reduces heigh-
tened air trapping by a mechanical maneuver, is a practical and 
simple technique that can be taught quickly and can make 
a substantial difference to patients (Supplementary Figure 2). 
Pulmonary rehabilitation improves symptoms, reduces hospi-
tal readmissions, increases activity levels, and decreases levels 
of anxiety and depression.5,37 Although programs can be diffi-
cult to implement in some areas, largely because of low reim-
bursement rates, pulmonary rehabilitation is one of the single 
best treatments for patients with COPD.37 Exercise programs, 
disease education, and setting activity goals for patients can be 
helpful when pulmonary rehabilitation is not available.5 
Finally, ensuring that patients with COPD receive all indicated 
immunizations (eg, influenza, pneumococcal pneumonia,5 
Tdap, and Zoster) is important to overall patient care and 
may help to reduce exacerbations and other poor outcomes.
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Referral to a pulmonologist may be considered at diag-
nosis, at discharge after hospitalization for an exacerba-
tion, or when symptoms progressively deteriorate.5
Chronic Disease Management
Chronic disease management involves regular evaluation to 
monitor disease progression and treatment response. For 
COPD, important aspects include monitoring symptom bur-
den and exacerbation frequency, reviewing and observing 
device/inhaler technique, reviewing medication adherence, 
and updating any action plans. But, patient evaluation and 
treatment are a continuous process and cannot be accom-
plished in a single visit. A COPD action plan should be 
developed and individualized for each patient; however, 
development is often not logical or feasible until the second 
or third visit. The COPDF action plan,38 which was designed 
to improve communication between clinicians and patients 
with COPD, and to encourage disease self-management, 
should be considered (Supplementary Figure 3). Further, 
while these regular evaluations are essential to achieve opti-
mal treatment outcomes, evidence indicates clinicians and 
patients do not necessarily appreciate their importance. For 
example, according to results of quantitative, web-based, 
descriptive, cross-sectional surveys of clinicians and patients 
with COPD in the United States, both groups had limited 
concerns about proper device use.39 Less than half of the 
Figure 3 Nonpharmacological management of COPD at diagnosis and follow-up. 
Notes: Reproduced with permission from Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Prevention, Diagnosis, and Management of Chronic 
Obstructive Pulmonary Disease. 2020. https://goldcopd.org.5 
Abbreviation: Flu, influenza.
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clinicians surveyed reported assessing device technique in 
every newly diagnosed patient, and many reported not routi-
nely assessing and inconsistently educating about proper 
device use. Not surprisingly, incorrect inhaler use led to 
poor clinical outcomes.
Patient education is important in ensuring successful disease 
management and optimal medication adherence and compliance. 
Regular demonstrations and direct observations of patients’ use 
of their medication delivery systems should be done at each visit 
to ensure proper use. In addition, patients should be reminded 
that although serious, COPD symptom burden and progression 
may be modifiable with treatment and behavioral changes.
As mentioned, an important aspect of patient education 
is smoking cessation.40 Motivating current smokers with 
COPD to quit may be particularly challenging because 
they continue to smoke despite disease symptoms. “Lung 
age” may be a useful tool to demonstrate the effects of 
cigarette smoking and is known to increase smoking 
Figure 4 Effects of smoking on COPD risk and lung age. 
Notes: Adapted with permission from Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1(6077):1645–1648, Copyright© 1977 
BMJ Publishing Group Ltd.41 COPD risk and smoking cessation:41,42 effects of smoking and smoking cessation on FEV1 in patients who are likely to develop COPD if 
they smoke are illustrated by solid lines. The graphs represent cross-sectional data from several individuals measured at different time points. Although the rate of 
loss of FEV1 for a susceptible smoker is shown, others may experience different rates of loss, and reach “disability” at different ages. While the underlying cause of 
“Death” is irreversible COPD, the immediate cause may be pneumonia, cor pulmonale, respiratory failure, or aggravation of heart disease by respiratory insufficiency. 
Adapted from Doherty DE. A review of the role of FEV1 in the COPD paradigm. COPD. 2008;5(5):310–318, Copyright© 2008. Taylor and Francis.
42 Lung age:42 
Nonsmokers or smokers who are not susceptible to the effects of tobacco smoke experience a normal decline in lung function (blue line). Susceptible smokers 
experience an accelerated loss of lung function over time (orange line). For example, if the FEV1 of a susceptible 40-year-old smoker (measured at 75% predicted; 
dotted vertical line) is extrapolated (horizontal line drawn to the curve of a nonsmoker/non-susceptible smoker), the “Lung Age” is approximately 74 years, suggesting 
that the lung function is equivalent to that of a nonsmoker/non-susceptible smoker at 74 years. 
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second.
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cessation rates.40 In addition, spirometry curves (Figure 4) 
are helpful in demonstrating that quitting smoking even at 
a late age can reduce morbidity and mortality.40–42
Ensuring continuity of care over time is central to 
chronic disease management programs, including those for 
COPD. During repeated visits, clinicians must confirm that 
patients are prescribed and are taking appropriate COPD 
maintenance therapy, addressing smoking cessation, offered 
support for an increased activity or pulmonary rehabilita-
tion, and considered as candidates for palliative (not just 
end-of-life) care. All of these activities are especially impor-
tant following any hospital admission for an exacerbation.
Conclusions
COPD is a leading cause of morbidity and mortality in the 
United States. Because most patients with COPD are mana-
ged in the primary care setting, primary care clinicians play 
a pivotal role in appropriately managing COPD. Following 
up-to-date treatment recommendations such as those pro-
vided in the GOLD 2020 strategy report, engaging in chronic 
disease management, and investing in patient education are 
important to achieve the greatest benefits of COPD treatment.
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